BioNTech buys German site from Novartis: the advisor

BioNTech, has agreed to acquire the GMP certified manufacturing facility in Marburg, Germany of Novartis, a listed Switzerland-based company engaged in pharmaceutical company. The transaction will increase BioNTech’s Covid-19 vaccine production capacity by up to 750m doses per year, or over 60m doses per month, once fully operational. The transaction is expected to complete in the fourth quarter of 2020 and is subject to regulatory approval and customary closing conditions.

Freshfields Bruckhaus Deringer acted as legal advisor to Novartis.

BioNTech buys German site from Novartis: the advisor


Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2023 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram